Clinical trial · Observational
Transradial Versus Transfemoral Arterial Access in Liver Cancer Embolization: Randomized Trial to Assess Patient Outcomes and Satisfaction (BEST ACCESS Trial).
Transradial Versus Transfemoral Arterial Access for Transarterial Embolization Therapy of Hepatic Carcinoma: A Patient Outcomes, Satisfaction, and Cost Analysis
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the safety, advantages, and appropriateness of performing transarterial hepatic emobolization of liver cancer via arterial access from the radial artery versus conventional transfemoral arterial access. The procedures that will be followed utilizing arterial access include transarterial chemoembolization (TACE), specifically performed for hepatocellular carcinoma, and transarterial embolization (TAE) which is performed for types of liver tumors such as carcinoid tumors or liver metastases.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemoembolizaton | — | UNRESOLVED | — |
| Hepatic Carcinoma | Hepatocellular Carcinoma | PROBABILISTIC | 0.70 |
| Transarterial Embolization | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Transarterial embolization | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To assess potential patient preference for the performance of hepatic embolization procedures via transradial versus transfemoral approach.
- timeFrame
- December, 2015 through August, 2016
- description
- Record of patient response via administered questionnaire as well as stated patient choice in the selection of approach for the third planned procedure of a series. These findings will be correlated with additional objective data regarding complication rates.
Secondary outcomes (3)
- measure
- To evaluate complication rates and severity from different modes of access.
- timeFrame
- December, 2015 through August, 2016
- description
- This data will be collected from imaging, clinical, and laboratory measures of complications collected at both the one day and follow-up clinic visits.
- measure
- To assess ancillary procedural and patient satisfaction quality metrics between the two groups.
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age \> 18 years 2. Selected for TACE treatment of Barcelona Clinic Liver Cancer Staging System stage B disease per current standard of care or TAE for the treatment of hepatic carcinoma 3. Radial diameter of ≥2.0mm as determined by clinical and ultrasound evaluation 4. Patient undergoes at least two of three courses of planned treatment with TACE/TAE per institutional protocol Exclusion Criteria: 1. Need for additional procedures requiring transfemoral or transradial access approach during the same hospitalization 2. Patient is unable to give informed consent in accordance with guidelines established the Institutional Review Board. 3. Unsuitable for radial access due lack of dual arterial supply to the hand as determined by modified Allen test. 4. Female patients who are pregnant, breastfeeding, or premenopausal and not using an effective method of contraceptive.
References
Publications (0)
Data not yet available